UroGen Pharma, which is developing formulations of a chemotherapy to treat urological cancers, filed on Friday with the SEC to raise up to $50 million in an initial public offering.
The Ra'anana, Israel-based company was founded in 2004 and plans to list on the Nasdaq under the symbol URGN. UroGen Pharma filed confidentially on March 4, 2016. Jefferies and Cowen & Company are the joint bookrunners on the deal. No pricing terms were disclosed.
